Search | Page 43 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Sapacitibine shows promise for high-risk MDS patients

    ... factors, to intensive therapy with allogeneic hematopoietic stem cell transplantation (HSCT). Treatment selection should be based on the ... can help decrease the growth of abnormal bone marrow cells and  restore gene expression.  Failure of the hypomethylating agents, ...

    Research Review last updated 05/02/2016 - 9:30am.

  2. B. Douglas Smith, MD

    ... on studying the impact of the treatment on the leukemic stem cell in hopes of limiting these cells’ roles in treatment failure.   Dr. Smith serves on the NCCN ...

    Bio last updated 03/11/2016 - 1:41pm.

  3. Chao-Yie Yang

    ... key proteins that prevent programmed cell death in cancer cells. One compound, AT-406, is currently entering a phase 2 clinical trial ... (GvHD) for treating patients receiving hematopoietic stem cell transplantation with a collaborator at Indiana University. The ...

    Bio last updated 03/11/2016 - 1:41pm.

  4. Conferences, Webinars and Webcasts

    ...   Caregivers   Clinical Trials   Stem Cell Transplantation   Living Well   Nutrition   ... is a rare and serious blood disease that causes red blood cells to break apart. Doctors call this breaking apart " hemolysis ". It ...

    Page last updated 09/30/2014 - 11:50am.

  5. Interviews with the Experts Managing MDS With Supportive Care and Active Treatment

    ... is a longer acting growth factor for white blood cells. These growth factors can sometimes be considered to be part of a ... MDS, one that is potentially curative, is an allogeneic stem cell transplant , but not all patients are suited for or otherwise ...

    Interview last updated 09/22/2014 - 12:25pm.

  6. 2014 Scholarships Awarded to Special Group of Young People

    ... and radiation? Can we regenerate the patient’s own stem cells without requiring a transplant? As a curious person, I am haunted by ...

    Page last updated 10/22/2015 - 8:28am.

  7. ASH 2012 - Reviewing MDS Progress from Research and Clinical Perspectives

    ... systems that involve something called “induced pluripotent stem cells” or iPSCs. These are cells created in the laboratory that can be grown ...

    Interview last updated 02/01/2013 - 4:22pm.

  8. North American Pediatric Aplastic Anemia Consortium Symposium

    ... that causes the bone marrow to stop making blood cells.  As with all rare diseases, there is a relative lack of research to ... exists, particularly with advances in hematopoietic stem cell transplantation (HSCT). Experts in HSCT, Drs Leslie Lehmann ... 90%. The typical time to transplant is 4-6 weeks. The ideal stem cell source is generally accepted to be bone marrow as peripheral blood ...

    Page last updated 10/31/2013 - 4:06pm.

  9. Eltrombopag now an approved therapy for certain patients with severe aplastic anemia

    ... therapy and are not candidates for a hematopoietic stem cell transplant. Eltrombopag, works by helping to increase production of blood cells. According to Cynthia Dunbar, M.D., Head, Molecular ...

    Page last updated 08/27/2014 - 2:19pm.

  10. Scientific Symposium Co-Chair Richard Stone, MD Discusses Progress and New Directions in Bone Marrow Failure Disease Research

    ... can be an ‘immunopathy’, causing inhibition of normal stem cell development, or a telomeropathy caused by mutation in genes ... in some cases using both of these together with the haplo cells helping to get blood counts to recover faster, with the cord blood ...

    Interview last updated 04/29/2014 - 12:01pm.